Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?

by Zacks Equity Research

Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.

    Zacks Equity Research

    Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio

    by Zacks Equity Research

    Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.

      Zacks Equity Research

      Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

      by Zacks Equity Research

      Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

        Zacks Equity Research

        Abbott to Strengthen Vascular Care Arm With Surmodics Deal

        by Zacks Equity Research

        Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.

          Zacks Equity Research

          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

          by Zacks Equity Research

          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

            Zacks Equity Research

            Abbott (ABT) Down 6.7% Since Earnings Report: Can It Rebound?

            by Zacks Equity Research

            Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Zacks Equity Research

              FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

              by Zacks Equity Research

              FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

                Zacks Equity Research

                Cardiovascular Systems Portfolio Solid, Competition Rife

                by Zacks Equity Research

                Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.

                  Zacks Equity Research

                  Abbott's FreeStyle LibreLink App Now Available in Europe

                  by Zacks Equity Research

                  Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.

                    Zacks Equity Research

                    Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View

                    by Zacks Equity Research

                    Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.

                      Zacks Equity Research

                      Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View

                      by Zacks Equity Research

                      Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.

                        Zacks Equity Research

                        HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)

                        by Zacks Equity Research

                        HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.

                          Zacks Equity Research

                          MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN

                          by Zacks Equity Research

                          The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.

                            Zacks Equity Research

                            Boston Scientific's (BSX) Millipede Deal Aids MR Business

                            by Zacks Equity Research

                            Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.

                              Zacks Equity Research

                              Markets Keep Gaining Amid Strong Corporate Earnings

                              by Zacks Equity Research

                              Markets Keep Gaining Amid Strong Corporate Earnings

                                Mark Vickery headshot

                                Plethora of Q4 Earnings Amid New Market Highs

                                by Mark Vickery

                                From GE and Comcast to United Technologies and General Dynamics, the latest round of Q4 earnings results is accounted for.

                                  Zacks Equity Research

                                  Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance

                                  by Zacks Equity Research

                                  Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.

                                    Zacks Equity Research

                                    Abbott (ABT) Beats Earnings and Revenue Estimates in Q4

                                    by Zacks Equity Research

                                    Abbott (ABT) rides high on new product approvals and launches in Q4.

                                      Tracey Ryniec headshot

                                      This Week's Amazing Earnings Charts

                                      by Tracey Ryniec

                                      These 5 companies have consistently beat the earnings estimate. Will they do it again?

                                        Zacks Equity Research

                                        Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?

                                        by Zacks Equity Research

                                        Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.

                                          Zacks Equity Research

                                          Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

                                          by Zacks Equity Research

                                          Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

                                            Zacks Equity Research

                                            Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre

                                            by Zacks Equity Research

                                            Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.

                                              Zacks Equity Research

                                              Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

                                              by Zacks Equity Research

                                              Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

                                                Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                                  Zacks Equity Research

                                                  Abbott (ABT) at a 52-Week High: What's Driving the Stock?

                                                  by Zacks Equity Research

                                                  Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.